Evgen Pharma Share Discussion Threads

[amaretto1] 24/12/2020 07:46

It will be at 8 !!

[bumpa33] 24/12/2020 07:31

the Sun is claiming major victory yet sterling is barely up first thing, so I’m guessing the detail will be nothing to write home about. Still, a deal - of sorts - is better than nothing at all, I guess.

[amaretto1] 24/12/2020 07:09

8am Brexit deal done !!!

[gimmetheloot] 23/12/2020 23:25

A veg tablet v a vaccine that everyone is suspicious of? No brainier.

[bocker01] 23/12/2020 23:20

That’s pretty spot on Loot. Though knowing how leaky the corrupt ship Finncap is, I wouldn’t be at all surprised if MM is right about good news around the corner. Wouldn’t want to be out over the rather extended weekend!

[gimmetheloot] 23/12/2020 23:01

This is EVG not SNG. We are targeting ARDS. If this trial comes good we will be bought out for around £10 per share. 10-11p atm. Do the maths. Like money munch posted the other day big pharmas are desperate for a vaccine free treatment.

[moneymunch] 23/12/2020 22:53

A few more boxes of sardines, prawns, lobsters
and scallops clinched the deal...
Zut Alors...😁
28513;😁€378;💪㈇7;🥳🥳🥳🕺🕺🕺8170;👍ԅ18;

[mam fach] 23/12/2020 22:52

Looks like good news on the way.
Will we have to wait till next week or longer?
Happy to have bought at close to bottom.
GLA

[moneymunch] 23/12/2020 22:24

In Boris we trust...ho ho ho...well almost...it can't be easy...:-)))

[moneymunch] 23/12/2020 22:22

So the f'ing Countries of Europe want to keep selling their cars and endless goods into their number one customer in Europe...ha ha ha ...who would have thought...ho ho ho....the UK is about to start another chapter in its illustrious history...On and most definitely UP....Fill Ya Boots!!! :-)

[moneymunch] 23/12/2020 21:13

Pps endless documented evidence and research that suggests that SFX-01's chances are up there with the very best. :-)

[moneymunch] 23/12/2020 21:02

Ps Eulicid, we all need to know what the assessment of the first 100 patients in the Covid-19 patient trials will be...not nice if no good, but certainly not the end for Evgen, and if good, then we're heading for the Stars....let's hope the name of the Covid-19 trial is more than just a coincidence....Gl :-)

[moneymunch] 23/12/2020 20:55

Lazy b'stards who have too many fingers in too many pies to give a jot....until the time is right....that just might be coming with any luck...Gl.:-)

[euclid5] 23/12/2020 20:37

Surprised that FinnCap hasn't altered their PT from their 25p, that excludes SFX-01 for Covid 19 use. Unless they need to see that it works from their Phase II/III testing first

[moneymunch] 23/12/2020 20:24

There's been a raft of commercial deals over the last year, many worth $100m's , involving early stage bio's focussed, on STAT3 or NRF2 and also SHP2 , all of which SFX-01 appears to have a potent therapeutic effect......yet Evgen's market cap is still only £15m with a phase 2/3 ARDS/ Covid patient trial underway, and awaiting data for a phase2b breast cancer trial to commence, where phase 2 data was outstanding and life changing for some patients, as well as disclosure on a collaborator on some of the best Solid Tumour preclinical data ever seen for a hard to treat cancer , as well as the rest of the promising pipeline focussed on multiple disease targets, not to mention the licensing deal with Jim Mellon worth $10.5m and royalties thereafter......sooner or later a Major will show their hand, or positive trial data and progress will propel Evgen's share price to fair market value and beyond...Gla ;-)

.........

Scopus BioPharma Stock Price Surged Over 300% In Public Debut

December 18, 2020



The stock price of Scopus BioPharma (NASDAQ: SCPS) increased from $8.17 at 11 AM ET on December 16 to $33.96 on December 17 at 4 PM ET. Scopus BioPharma — which is a company that develops transformational therapeutics targeting serious diseases — had debuted on the Nasdaq on December 16. The company’s lead program is a targeted immuno-oncology gene therapy for the treatment of multiple cancers.

................

Back in June, Scopus BioPharma said it is licensing novel immuno-oncology gene therapy drug from the City of Hope. The City of Hope is a world-renowned independent research and treatment center for cancer, diabetes, and other life-threatening diseases near Los Angeles, California.

And the licensed gene therapy drug CpG-STAT3siRNA (or the STAT3 inhibitor) is a highly-selective and targeted therapy that silences the activity of the STAT3 gene by way of RNA interference while stimulating the TLR9 receptors to activate the body’s immune defense to recognize and kill cancer cells.

In pre-clinical testing, the STAT3 inhibitor successfully reduced growth and metastasis of various pre-clinical tumor models, including melanoma, colon and bladder cancers, as well as leukemia and lymphoma. A first-in-human Phase 1 clinical trial in B-cell lymphoma patients was scheduled to commence in H2 2020 at City of Hope.

The STAT3 drug was developed at City of Hope by Hua Yu, Ph.D., Associate Chair and Professor in the Department of Immuno-Oncology, Co-leader of the Cancer Immunotherapeutics Program and Billy and Audrey L. Wilder Professor in Tumor Immunotherapy at City of Hope, and Marcin Kortylewski, Ph.D., Associate Professor in the Department of Immuno-Oncology at City of Hope — who are both leading experts in the role of STAT3 in tumor angiogenesis and tumor immune evasion and in oligonucleotide-based cancer immunotherapies. And the strategy was developed based on seminal discoveries by Dr. Yu’s team defining the key role of STAT3 in cancer cell survival and immune tolerance combined with a pioneering work on STAT3 targeting using TLR9-targeted delivery of siRNA oligonucleotide therapeutics into immune cells by Dr. Kortylewski and her team.

[moneymunch] 23/12/2020 19:26

Yep, touch wood. :-)

[amaretto1] 23/12/2020 16:58

Been adding today at 11 I'm confident here..... intuition worked all year... for some reason :-)

[ali g2] 23/12/2020 14:08

double auction!?!

[moneymunch] 23/12/2020 13:44

Yep, of course my mistake, i was dividing £1 by 137m for some reason.....anyways £137m market cap would be cheap as chips for any bio with encouraging phase 2/3 data for ARDS/Covid.....plenty of other news also expected....Gl ;-)

[brasso3] 23/12/2020 13:40

137m shares x 100p = £137m market cap.

moneymunch23 Dec '20 - 13:38 - 6163 of 6165

Not at all brasso....interim positive data from SFX-01's Covid trial could easily see the share price at £1 which would equate to a market cap of £72m

[moneymunch] 23/12/2020 13:40

15p could go today at this rate.....Gl ;-)

[brasso3] 23/12/2020 13:32

MM

I think that is a stretch at 11p! We should be focused on the short term 15p resistance at the moment.

[moneymunch] 23/12/2020 13:31

Any positive news on SFX-01 for Covid and this will sail past £1 plus and more.....Tick Tock....;-)